Ann Bass

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 896 citations

Neurological Disorder, Clinical Neurology, Clinical Trials +9

Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 Clinical Trial

Alasdair Coles, Edward Fox, Anton Vladić et al. · Neurology · 2012 · 260 citations

Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes

Alasdair Coles, Edward Fox, Anton Vladić et al. · The Lancet Neurology · 2011 · 138 citations

Rheumatology, Clinical Efficacy Outcomes, Autoimmune Disease +9

Autoimmune mechanisms in thromboangiitis obliterans (Buerger's disease): the role of tobacco antigen and the major histocompatibility complex.

Moshe Z. Papa, Ann Bass, R Adar et al. · PubMed · 1992 · 81 citations

The T4 surface antigen is involved in the induction of helper function.

L Rogozinski, Ann Bass, E Glickman et al. · The Journal of Immunology · 1984 · 77 citations